Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with... Oncol Ther (2016) 4:211–223 DOI 10.1007/s40487-016-0027-x ORIGINAL RESEARCH A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study . . . Ve ´ ronique Die ´ras Thomas Bachelot Mario Campone . . . . Nicolas Isambert Florence Joly Christophe Le Tourneau Philippe Cassier . . . Emmanuelle Bompas Pierre Fumoleau Sabine Noal . . . Christine Orsini Marta Jimenez Diane Charlotte Imbs Etienne Chatelut Received: May 25, 2016 / Published online: August 18, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com were planned. MTD was based on DLT observed ABSTRACT during cycles 1 and 2. Introduction: To determine the feasibility, Results: Thirty-five patients were enrolled. The maximum-tolerated dose (MTD), and MTD was reached at the first DL, (pazopanib dose-limiting toxicities (DLT) of pazopanib in 400 mg daily ? cisplatin 75 mg/m every combination with cisplatin. 21 days). Main DLTs were pulmonary Methods: Patients with advanced malignancies embolism, neutropenia, thrombocytopenia, were included in a 3 ? 3 dose-escalation phase I and elevation of liver enzymes. Overall, most study. Pazopanib administration started 8 days common adverse events were anemia (83%), before the first infusion of cisplatin; http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

Loading next page...
 
/lp/springer-journals/a-phase-i-dose-escalation-trial-of-pazopanib-in-combination-with-Oxy2tYLBT6
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0027-x
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:211–223 DOI 10.1007/s40487-016-0027-x ORIGINAL RESEARCH A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study . . . Ve ´ ronique Die ´ras Thomas Bachelot Mario Campone . . . . Nicolas Isambert Florence Joly Christophe Le Tourneau Philippe Cassier . . . Emmanuelle Bompas Pierre Fumoleau Sabine Noal . . . Christine Orsini Marta Jimenez Diane Charlotte Imbs Etienne Chatelut Received: May 25, 2016 / Published online: August 18, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com were planned. MTD was based on DLT observed ABSTRACT during cycles 1 and 2. Introduction: To determine the feasibility, Results: Thirty-five patients were enrolled. The maximum-tolerated dose (MTD), and MTD was reached at the first DL, (pazopanib dose-limiting toxicities (DLT) of pazopanib in 400 mg daily ? cisplatin 75 mg/m every combination with cisplatin. 21 days). Main DLTs were pulmonary Methods: Patients with advanced malignancies embolism, neutropenia, thrombocytopenia, were included in a 3 ? 3 dose-escalation phase I and elevation of liver enzymes. Overall, most study. Pazopanib administration started 8 days common adverse events were anemia (83%), before the first infusion of cisplatin;

Journal

Oncology and TherapySpringer Journals

Published: Aug 18, 2016

References